Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on May 12, 2022. The filing reports financial results for the three months ended March 31, 2022, along with recent corporate updates. The detailed financial data is contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K document.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only indicates that such results were reported on May 12, 2022.
Guidance, Outlook, and Risks
The filing text does not include specific guidance, outlook, management commentary, risks, contingencies, or unusual items. It serves as a notification that these details are available in the accompanying press release.
Investor Verification Checklist
- Verify the correct registrant name is Salarius Pharmaceuticals, Inc. (SLRX), not Decoy Therapeutics Inc.
- Review Exhibit 99.1 (Press Release) for actual financial figures, as they are not listed in the 8-K text.
- Confirm the reporting period is the quarter ended March 31, 2022.
- Note that the information in Item 2.02 is furnished and not deemed "filed" for liability purposes under Section 18 of the Exchange Act.